Flown the coop. Find me on bluesky or threads. Not yet sure which one will win. Peace out.
Jun 6, 2022 • 6 tweets • 2 min read
Dr Veneziani up presenting the PESCO trial
Maveropepimut-S targets Survivin protein
Jun 6, 2022 • 6 tweets • 2 min read
Hmmm. I am noticing that ex-US trials are not reporting race... Should this be a required element for @ASCO presentations?
Study design of MITO-23
Jun 6, 2022 • 5 tweets • 2 min read
Study volunteers: 35% had platinum-refractory disease and 6% had primary platinum-refractory disease. 12% had a BRCA mutation
Jun 6, 2022 • 9 tweets • 3 min read
This should be interesting as I am running a trial in clear cell cancer with colleagues @BrownOncology
Presented by my fellow Matt Hadfield at #ASCO22
This should be interesting as I am running a trial in clear cell cancer with colleagues @BrownOncology
Presented by my fellow Matt Hadfield at #ASCO22
Jun 6, 2022 • 7 tweets • 2 min read
Next up #gyncsm#ASCO22 Ruxolitinib
Ruxolitinib = JACK 1/2 inhibitor. The IL-6/JAK/STAT3 implicated in the survival of cancer stem like cells. Inhibition of this axis may improve the activity of chemotherapy.
Jun 6, 2022 • 5 tweets • 2 min read
#gyncsm ATHENA-MONO volunteers
75% White, 22% Asian.
This will be a problem going forward. Volunteers on trials should represent the demographics of those who get the disease.
FWIW: Ref SEER (Cases per 100K persons)
ATHENA-MONO Progression free survival favors rucaparib over placebo in volunteers with HRD
Jan 7, 2022 • 9 tweets • 1 min read
The Omicron surge has been truly devastating... for cancer centers. 🧵 1/9
Operating rooms are operating, but on a day by day basis as staff are sent elsewhere to cover. 2/9